Seung Hyun Jung
Research Subjects
Research Interests
Seung Hyun Jung has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Joo-Yun Byun
School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
3 shared publications Kwee Hyun Suh
Hanmi Pharm.Co.,Ltd., Hwaseong-si, Korea, Republic of
3 shared publicationsYoung Gil Ahn
Hanmi Pharm.Co.,Ltd., Hwaseong-si, Korea, Republic of
3 shared publications- Young Hoon Kim
Department of Psychiatry, Gongju National Hospital, Gongju, Republic of Korea
3 shared publications Yu-Yon Kim
Hanmi Pharm.Co.,Ltd., Hwaseong-si, Korea, Republic of
3 shared publicationsJaeyul Choi
Hanmi Pharm.Co.,Ltd., Hwaseong-si, Korea, Republic of
2 shared publications
Latest Publications
- Open Access
- 1 December 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (12_Supplem) , A144
Abstract A144: HM99462, a Novel & potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inhibitor, MEK inhibitor, or EGFR mutant inhibitor
Son of sevenless homolog 1 (SOS1) is one of guanine nucleotide exchange factor (GEF) responsible for a binary molecular switch to activate KRAS as well as a node in the negative feedback loop in the RTK-KRAS-MAPK signaling pathway. Therefore, combination strategies with a SOS1 inhibitor are being explored as a promising therapeutic options to target the MAPK-mediated bypass, which may improve antitumor activity or delay the induction of resistance after treatment. Herein, we presented a novel and potent SOS1 inhibitor, HM99462, which abrogates GTP-binding to KRAS and the profile of drug potency and mechanism of action was examined with in vitro and in vivo models. Biochemical activity on SOS1 was evaluated by a GTP-exchange assay on diverse KRAS G12X mutant types, NRAS Q61H, and HRAS G12V, and HM99462 showed excellent inhibitory activity, while SOS2 action was not affected. Moreover, HM99462 decreased ERK phosphorylation in various cancer cell lines harboring different major KRAS mutation statuses such as KRAS G12C, G12D, G12V, or G13D. Growth inhibition assay was performed using a three-dimensional (3D) conformation culture that mimics the complexity and heterogeneity of tumors and has elevated p-ERK. In this 3D spheroid growth inhibition assay, HM99462 demonstrated significantly effective GI50 against various KRAS mutant cancer cell lines. Additionally, HM99462 was evaluated in cancer cell xenograft mouse models harboring KRAS or EGFR mutation. The combination of HM99462 with KRAS G12C, MEK, or EGFR mutant inhibitor led to significantly synergistic anti-tumor activity in both in vitro and in vivo models with several KRAS or EGFR mutations. Based on our exploratory study, a novel and potent SOS1 inhibitor, HM99462 could be suggested as an appropriate therapeutic agent for diverse inhibitory activity against cancers causing by the hyperactivation of oncogenic KRAS or RTK signaling. And it has the potential to overcome the limitations of KRAS G12C, MEK or EGFR inhibitor through combination. IND enabling GLP-toxicity studies with HM99462 are currently underway, and we planned to initiate clinical study in early 2024. Citation Format: Jaeyul Choi, Seung Hyun Jung, Wongi Park, Jooyun Byun, Semi Lim, Youngjoo Lee, Soye Jeon, Yu-Yon Kim, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh. HM99462, a Novel & potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inhibitor, MEK inhibitor, or EGFR mutant inhibitor [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A144.
- 1 December 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (12_Supplem) , A144
Open AccessAbstract A144: HM99462, a Novel & potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inhibitor, MEK inhibitor, or EGFR mutant inhibitor
Son of sevenless homolog 1 (SOS1) is one of guanine nucleotide exchange factor (GEF) responsible for a binary molecular switch to activate KRAS as well as a node in the negative feedback loop in the RTK-KRAS-MAPK signaling pathway. Therefore, combination strategies with a SOS1 inhibitor are being explored as a promising therapeutic options to target the MAPK-mediated bypass, which may improve antitumor activity or delay the induction of resistance after treatment. Herein, we presented a novel and potent SOS1 inhibitor, HM99462, which abrogates GTP-binding to KRAS and the profile of drug potency and mechanism of action was examined with in vitro and in vivo models. Biochemical activity on SOS1 was evaluated by a GTP-exchange assay on diverse KRAS G12X mutant types, NRAS Q61H, and HRAS G12V, and HM99462 showed excellent inhibitory activity, while SOS2 action was not affected. Moreover, HM99462 decreased ERK phosphorylation in various cancer cell lines harboring different major KRAS mutation statuses such as KRAS G12C, G12D, G12V, or G13D. Growth inhibition assay was performed using a three-dimensional (3D) conformation culture that mimics the complexity and heterogeneity of tumors and has elevated p-ERK. In this 3D spheroid growth inhibition assay, HM99462 demonstrated significantly effective GI50 against various KRAS mutant cancer cell lines. Additionally, HM99462 was evaluated in cancer cell xenograft mouse models harboring KRAS or EGFR mutation. The combination of HM99462 with KRAS G12C, MEK, or EGFR mutant inhibitor led to significantly synergistic anti-tumor activity in both in vitro and in vivo models with several KRAS or EGFR mutations. Based on our exploratory study, a novel and potent SOS1 inhibitor, HM99462 could be suggested as an appropriate therapeutic agent for diverse inhibitory activity against cancers causing by the hyperactivation of oncogenic KRAS or RTK signaling. And it has the potential to overcome the limitations of KRAS G12C, MEK or EGFR inhibitor through combination. IND enabling GLP-toxicity studies with HM99462 are currently underway, and we planned to initiate clinical study in early 2024. Citation Format: Jaeyul Choi, Seung Hyun Jung, Wongi Park, Jooyun Byun, Semi Lim, Youngjoo Lee, Soye Jeon, Yu-Yon Kim, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh. HM99462, a Novel & potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inhibitor, MEK inhibitor, or EGFR mutant inhibitor [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr A144.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 1625
Abstract 1625: A novel SOS1 inhibitor, HM99462 demonstrates antitumor activity against KRAS-mutant cancers
KRAS is a well-known oncogene with the highest mutation rate among various cancers. KRAS cycles between GDP-loaded ‘off’ and GTP-loaded ‘on’ states induce downstream signal transduction to promote cell proliferation and survival. Interconversion between ‘on’ and ‘off’ states is assisted by SOS (Son of sevenless), a binary molecular switch of KRAS. SOS family as a guanine-nucleotide exchange factor (GEF) is composed of SOS1 and SOS2, but SOS1 is a node in the negative feedback regulation of the KRAS pathway while SOS2 is not. Since SOS1 is a direct upstream of KRAS, SOS1 inhibitor has the potential to be a pan-KRAS inhibitor affecting various cancers harboring diverse KRAS mutations. Here, we suggest HM99462 as a novel SOS1 inhibitor for KRAS regulation and present its promising druggability. We developed HM99462 for an orally bioavailable SOS1 inhibitor which abrogates GTP-binding to KRAS and the profile of drug potency and mechanism of action was examined with in vitro and in vivo models. Biochemical activity on SOS1 was evaluated by a GTP-exchange assay on KRAS G12C, D, and V, and HM99462 showed excellent inhibitory activity, while SOS2 action was not affected. Moreover, HM99462 decreased ERK phosphorylation in various cancer cell lines harboring different major KRAS mutation statuses such as KRAS G12C, G12V, G12D, or G13D. Growth inhibition assay was performed using a three-dimensional (3D) conformation culture that mimics the complexity and heterogeneity of tumors and has elevated p-ERK. In this 3D spheroid growth inhibition assay, HM99462 demonstrated significantly effective GI50 against various KRAS mutant cell lines. HM99462 also had almost no inhibition of seven CYP isozymes guided by the FDA, and a low plasma protein binding rate around 80%, offering high unbound drug concentration. Additionally, HM99462 was evaluated in cancer cell xenograft mouse models harboring various KRAS mutations. Reasonable tumor growth inhibition activity was shown within tolerable doses when administered alone. Also, the combination of HM99462 with KRAS G12C or MEK inhibitors led to synergistic anti-tumor activity in both in vitro and in vivo models with several KRAS mutations. Through our exploratory study, a novel SOS1 inhibitor, HM99462 could be suggested as an appropriate therapeutic agent for diverse inhibitory activity against cancers causing by the hyperactivation of oncogenic KRAS signaling. And it has the potential to overcome the limitations of KRAS G12C or MEK inhibitor through combination. HM99462 is currently in IND enabling GLP-toxicity studies, planned to initiate clinical study in early 2024. Citation Format: Seung Hyun Jung, Jaeyul Choi, Wongi Park, Jooyun Byun, Semi Lim, Youngjoo Lee, Yu-Yon Kim, Hyunjin Park, So-Ye Jeon, Taehun Song, Kyungjin Choi, Tae-yeon Kong, Heecheol Kim, Wook Jang, EunYoung Lee, Minhwa Kim, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh. A novel SOS1 inhibitor, HM99462 demonstrates antitumor activity against KRAS-mutant cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1625.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 1625
Abstract 1625: A novel SOS1 inhibitor, HM99462 demonstrates antitumor activity against KRAS-mutant cancers
KRAS is a well-known oncogene with the highest mutation rate among various cancers. KRAS cycles between GDP-loaded ‘off’ and GTP-loaded ‘on’ states induce downstream signal transduction to promote cell proliferation and survival. Interconversion between ‘on’ and ‘off’ states is assisted by SOS (Son of sevenless), a binary molecular switch of KRAS. SOS family as a guanine-nucleotide exchange factor (GEF) is composed of SOS1 and SOS2, but SOS1 is a node in the negative feedback regulation of the KRAS pathway while SOS2 is not. Since SOS1 is a direct upstream of KRAS, SOS1 inhibitor has the potential to be a pan-KRAS inhibitor affecting various cancers harboring diverse KRAS mutations. Here, we suggest HM99462 as a novel SOS1 inhibitor for KRAS regulation and present its promising druggability. We developed HM99462 for an orally bioavailable SOS1 inhibitor which abrogates GTP-binding to KRAS and the profile of drug potency and mechanism of action was examined with in vitro and in vivo models. Biochemical activity on SOS1 was evaluated by a GTP-exchange assay on KRAS G12C, D, and V, and HM99462 showed excellent inhibitory activity, while SOS2 action was not affected. Moreover, HM99462 decreased ERK phosphorylation in various cancer cell lines harboring different major KRAS mutation statuses such as KRAS G12C, G12V, G12D, or G13D. Growth inhibition assay was performed using a three-dimensional (3D) conformation culture that mimics the complexity and heterogeneity of tumors and has elevated p-ERK. In this 3D spheroid growth inhibition assay, HM99462 demonstrated significantly effective GI50 against various KRAS mutant cell lines. HM99462 also had almost no inhibition of seven CYP isozymes guided by the FDA, and a low plasma protein binding rate around 80%, offering high unbound drug concentration. Additionally, HM99462 was evaluated in cancer cell xenograft mouse models harboring various KRAS mutations. Reasonable tumor growth inhibition activity was shown within tolerable doses when administered alone. Also, the combination of HM99462 with KRAS G12C or MEK inhibitors led to synergistic anti-tumor activity in both in vitro and in vivo models with several KRAS mutations. Through our exploratory study, a novel SOS1 inhibitor, HM99462 could be suggested as an appropriate therapeutic agent for diverse inhibitory activity against cancers causing by the hyperactivation of oncogenic KRAS signaling. And it has the potential to overcome the limitations of KRAS G12C or MEK inhibitor through combination. HM99462 is currently in IND enabling GLP-toxicity studies, planned to initiate clinical study in early 2024. Citation Format: Seung Hyun Jung, Jaeyul Choi, Wongi Park, Jooyun Byun, Semi Lim, Youngjoo Lee, Yu-Yon Kim, Hyunjin Park, So-Ye Jeon, Taehun Song, Kyungjin Choi, Tae-yeon Kong, Heecheol Kim, Wook Jang, EunYoung Lee, Minhwa Kim, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh. A novel SOS1 inhibitor, HM99462 demonstrates antitumor activity against KRAS-mutant cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1625.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 3276
Abstract 3276: Overcoming immune checkpoint blockade resistance via EZH1/2 dual inhibition by HM97662 in KRAS/LKB1 mutated NSCLC
Immune checkpoint blockades (ICBs) are known as a promising treatment option against in advanced non-small-cell lung cancer (NSCLC). And KRAS is the most frequently mutated oncogene in NSCLC. However, KRAS mutation is not a significantly associated with survival benefit of ICBs. Mutations in LKB1 (aka STK11) and frequently co-occurring KRAS mutations are accompanied with poor survival in metastatic NSCLC immuno-oncology trials. Even tumor mutational burden is a proposed-potential biomarker for response to ICBs, there are therapeutic unmet needs in NSCLC patient with KRAS/LKB1 (KL) mutation. Epigenetic regulation lead to enhanced anti-tumor immunity of innate immune responses via inducing type I interferons. Also it drives to enhance adaptive immune responses by targeting T cell recognition factors as well as recruitment immune cells to tumor microenvironments (TMEs). Thus, we demonstrated the pharmacological inhibition of Enhancer of zeste homolog (EZH)1/2 enhance the efficacy of clinically available immunotherapies in KRAS/LKB1 mutated NSCLC. Previously, we reported that a novel EZH1/2 dual inhibitor, HM97662, has showed potently decreased global H3K27me3 and strong anti-proliferative activities against various hematological cancer cell lines with EZH2 activating mutations as well as solid tumor cell lines with negatively mutated components of regulatory protein complexes. In this study, we evaluated that HM97662 could induce of STING expression and STING-dependent cytokine production in KL mutant NSCLC cell lines. Furthermore, we explored anticancer effect by inducing immune modulation by EZH2 inhibitors in combination with an anti-PD-(L)1 agent was evaluated. As a result, HM97662 potently restored STING expression in KL mutated cell lines such as A549 and H460, but did not KRAS/p53 (KP) mutated H358 cells. HM97662 also dose-dependently increased the mRNA expression of CXCL10, IFN-α and IFN-β and secretion of CXCL10, IFN-α, CCL2, CCL3 and CCL5 at nanomolar concentrations in H460 cells. In accordance with this, HM97662 showed potent growth inhibition against H460 cells under co-culture condition with activated T cells. Moreover, HM97662 had superior anti-proliferation efficacy among the tested compounds in H460 cells with activated T cells, when it combined with anti-PD-L1 antibody avelumab. In our exploratory study, HM97662 increments the sensitivity of immune checkpoint inhibitor by restoration of STING expression and STING pathway related chemo/cytokine production in KRAS/LKB1 mutated NSCLC cell lines. These results demonstrate that HM97662 drives anti-cancer effect by immune modulation in combination with anti-PD-(L)1 agent, suggesting therapeutic potency to combination with ICBs by turning non-inflamed to inflamed TME. Clinical trials to prove the effectiveness of HM97662 identified in preclinical studies need to be carried out immediately. Citation Format: Jooyun Byun, DongJin Hong, Miyoung Lee, Soonho Kweon, Seung Hyun Jung, Yu-Yon Kim, Hyunjin Park, Junghwa Park, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh. Overcoming immune checkpoint blockade resistance via EZH1/2 dual inhibition by HM97662 in KRAS/LKB1 mutated NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3276.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 3276
Open AccessAbstract 3276: Overcoming immune checkpoint blockade resistance via EZH1/2 dual inhibition by HM97662 in KRAS/LKB1 mutated NSCLC
Immune checkpoint blockades (ICBs) are known as a promising treatment option against in advanced non-small-cell lung cancer (NSCLC). And KRAS is the most frequently mutated oncogene in NSCLC. However, KRAS mutation is not a significantly associated with survival benefit of ICBs. Mutations in LKB1 (aka STK11) and frequently co-occurring KRAS mutations are accompanied with poor survival in metastatic NSCLC immuno-oncology trials. Even tumor mutational burden is a proposed-potential biomarker for response to ICBs, there are therapeutic unmet needs in NSCLC patient with KRAS/LKB1 (KL) mutation. Epigenetic regulation lead to enhanced anti-tumor immunity of innate immune responses via inducing type I interferons. Also it drives to enhance adaptive immune responses by targeting T cell recognition factors as well as recruitment immune cells to tumor microenvironments (TMEs). Thus, we demonstrated the pharmacological inhibition of Enhancer of zeste homolog (EZH)1/2 enhance the efficacy of clinically available immunotherapies in KRAS/LKB1 mutated NSCLC. Previously, we reported that a novel EZH1/2 dual inhibitor, HM97662, has showed potently decreased global H3K27me3 and strong anti-proliferative activities against various hematological cancer cell lines with EZH2 activating mutations as well as solid tumor cell lines with negatively mutated components of regulatory protein complexes. In this study, we evaluated that HM97662 could induce of STING expression and STING-dependent cytokine production in KL mutant NSCLC cell lines. Furthermore, we explored anticancer effect by inducing immune modulation by EZH2 inhibitors in combination with an anti-PD-(L)1 agent was evaluated. As a result, HM97662 potently restored STING expression in KL mutated cell lines such as A549 and H460, but did not KRAS/p53 (KP) mutated H358 cells. HM97662 also dose-dependently increased the mRNA expression of CXCL10, IFN-α and IFN-β and secretion of CXCL10, IFN-α, CCL2, CCL3 and CCL5 at nanomolar concentrations in H460 cells. In accordance with this, HM97662 showed potent growth inhibition against H460 cells under co-culture condition with activated T cells. Moreover, HM97662 had superior anti-proliferation efficacy among the tested compounds in H460 cells with activated T cells, when it combined with anti-PD-L1 antibody avelumab. In our exploratory study, HM97662 increments the sensitivity of immune checkpoint inhibitor by restoration of STING expression and STING pathway related chemo/cytokine production in KRAS/LKB1 mutated NSCLC cell lines. These results demonstrate that HM97662 drives anti-cancer effect by immune modulation in combination with anti-PD-(L)1 agent, suggesting therapeutic potency to combination with ICBs by turning non-inflamed to inflamed TME. Clinical trials to prove the effectiveness of HM97662 identified in preclinical studies need to be carried out immediately. Citation Format: Jooyun Byun, DongJin Hong, Miyoung Lee, Soonho Kweon, Seung Hyun Jung, Yu-Yon Kim, Hyunjin Park, Junghwa Park, Young Gil Ahn, Young Hoon Kim, Kwee Hyun Suh. Overcoming immune checkpoint blockade resistance via EZH1/2 dual inhibition by HM97662 in KRAS/LKB1 mutated NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3276.
- Open Access
- 30 August 2017
- Published by Wiley in Phytotherapy Research
- Vol. 31 (11) , 1765-1775
Anticancer Effects of a Korean Herbal Medicine Formula (H9) via AMPK and HER2‐PI3K/Akt Signaling in Breast Cancer Cells
An H9 is a formula of nine medicinal herbs derived from Osuyubujaijung‐tang, a traditional Korean prescription for Soeumin constitution. In our previous study, H9 showed anticancer effects against breast cancer and non‐small‐cell lung cancer. However, the underlying mechanisms of these effects have not yet been elucidated. In this study, we investigated the effects of H9, both alone and in combination with trastuzumab, on breast cancer cells and sought to elucidate the mechanisms involved. H9 suppressed the proliferation of human breast cancer cells, induced arrest of the cell cycle at the G0/G1 phase, and caused mitochondrial dysfunction and apoptosis. In addition, H9 induced the activation of AMPK and inhibited the HER2‐PI3K/Akt signaling pathway. Furthermore, H9 attenuated hypoxia‐induced HIF‐1α and VEGF, resulting in decreased migration and invasion of breast cancer cells. Compared with treatment with either drug alone, co‐treatment with H9 and trastuzumab significantly inhibited the growth of BT‐474 cells through induction of apoptosis. These results suggest that H9 should be considered as a potent anticancer agent that targets the HER2‐PI3K/Akt pathway, and the combination of H9 with trastuzumab should be considered as a new therapeutic regimen for treating breast cancer. Copyright © 2017 John Wiley & Sons, Ltd.
- 30 August 2017
- Published by Wiley in Phytotherapy Research
- Vol. 31 (11) , 1765-1775
Open AccessAnticancer Effects of a Korean Herbal Medicine Formula (H9) via AMPK and HER2‐PI3K/Akt Signaling in Breast Cancer Cells
An H9 is a formula of nine medicinal herbs derived from Osuyubujaijung‐tang, a traditional Korean prescription for Soeumin constitution. In our previous study, H9 showed anticancer effects against breast cancer and non‐small‐cell lung cancer. However, the underlying mechanisms of these effects have not yet been elucidated. In this study, we investigated the effects of H9, both alone and in combination with trastuzumab, on breast cancer cells and sought to elucidate the mechanisms involved. H9 suppressed the proliferation of human breast cancer cells, induced arrest of the cell cycle at the G0/G1 phase, and caused mitochondrial dysfunction and apoptosis. In addition, H9 induced the activation of AMPK and inhibited the HER2‐PI3K/Akt signaling pathway. Furthermore, H9 attenuated hypoxia‐induced HIF‐1α and VEGF, resulting in decreased migration and invasion of breast cancer cells. Compared with treatment with either drug alone, co‐treatment with H9 and trastuzumab significantly inhibited the growth of BT‐474 cells through induction of apoptosis. These results suggest that H9 should be considered as a potent anticancer agent that targets the HER2‐PI3K/Akt pathway, and the combination of H9 with trastuzumab should be considered as a new therapeutic regimen for treating breast cancer. Copyright © 2017 John Wiley & Sons, Ltd.